Pathogen Inactivation

Search documents
Cerus(CERS) - 2024 Q3 - Earnings Call Presentation
2025-07-09 13:11
Financial Performance & Guidance - Cerus is raising its full-year 2024 product revenue guidance to $177 - $179 million, anticipating a 12-14% increase compared to full-year 2023 product revenue[13] - The bottom end of the 2024 IFC guidance range has been raised to $9 - $10 million, from the prior $8 - $10 million[13] - In Q3 2024, Non-GAAP Adjusted EBITDA reached $4.4 million[32] Product & Market - The global addressable market for INTERCEPT products is estimated at $1.3 billion, with potential growth to over $1.5 billion in 5-7 years[22] - The U S addressable market is $150 million, with potential growth to over $200 million in 5-7 years[22] - Cerus' preliminary 2023 product revenue was $156 million[22] Strategic Initiatives - Cerus has a new BARDA contract for INTERCEPT RBCs[11] - The company submitted a CE Mark for its LED Illuminator[11] - Cerus is focused on adjusted EBITDA and operating cash flow goals[25]
Cerus(CERS) - 2025 FY - Earnings Call Transcript
2025-06-11 13:40
Cerus (CERS) FY 2025 Conference June 11, 2025 08:40 AM ET Speaker0 Well, good morning, everyone. My name is Obi Greenman. I am the CEO of Cirrus. I'm here with my colleague, Kevin Green, who's the CFO of Cirrus in the back room there. I just want to thank Goldman Sachs for the opportunity to present our company Cirrus today. Before I start, I will want to acknowledge the forward looking statements that I'll be making today and encourage you all to read the SEC Form 10 Q and 10 ks risk factors just to be awa ...